Are Oral Dissolving Strips FDA Approved? ODF Regulation

Approved, registered, cleared: what the words mean

No dietary supplement is FDA approved, in any dosage form, and an oral dissolving strip sold as a supplement is no exception. FDA's own consumer guidance says: "By statute, the FDA does not approve dietary supplements for safety and effectiveness," and adds that "many dietary supplements can be marketed without even notifying the FDA." Anyone who tells you their supplement strips are FDA approved is describing an approved drug or contradicting the agency.

Facilities are not approved either. In FDA's words, "the agency does not approve manufacturing facilities independently," and registration "does not denote approval of the establishment." FDA registered means a facility has filed the registration required of food facilities that manufacture, process, pack, or hold food (which includes dietary supplements) for U.S. consumption, renewed every other year under the Food Safety Modernization Act.

What is actually required is the rest of this guide: a product that meets the DSHEA definition, including intended for ingestion; manufacturing under 21 CFR Part 111; labeling under 21 CFR Part 101; an NDI notification if an ingredient is new; claims that stay on the supplement side of the line; and a serious adverse event process. None of this is legal advice. Classification, label review, and claims substantiation are decisions for the brand and its regulatory counsel.

Three pathways: supplement, OTC monograph drug, or new drug

An oral dissolving film is a dosage form, not a regulatory category. The same strip can be a dietary supplement, an over-the-counter drug, or a prescription drug depending on what is in it and what it is for. Under 21 U.S.C. 321(g) a drug includes articles "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" and articles other than food "intended to affect the structure or any function of the body." DSHEA carves dietary supplements out of that second prong, so structure/function claims can be made without drug status, but only for a product that meets the supplement definition.

For nonprescription drugs FDA describes "two regulatory pathways for nonprescription drugs to come to market: the drug application process and the OTC drug monograph process." A monograph fixes the permitted actives, strengths, indications, and labeling for a category; a conforming product needs no application, but it is a drug, made under drug cGMP and labeled with Drug Facts. A new active, dose, or indication needs a new drug application.

Decide the pathway first. It determines the manufacturer, quality system, testing scope, label format, and what you may say. StripWorks scopes oral films as dietary supplements and does not quote drug-pathway products as supplements; the restricted actives guide shows where that line is most often crossed.

The DSHEA definition and the ingestion requirement

DSHEA (Public Law 103-417, October 25, 1994) added the dietary supplement definition to the Federal Food, Drug, and Cosmetic Act at section 201(ff), now 21 U.S.C. 321(ff). A dietary supplement is "a product (other than tobacco) intended to supplement the diet" containing one or more dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, "a dietary substance for use by man to supplement the diet by increasing the total dietary intake," or a concentrate, metabolite, constituent, extract, or combination of those.

Then come the form requirements. The product must be "intended for ingestion" in a form such as a tablet, capsule, powder, softgel, gelcap, or liquid, or otherwise intended for ingestion and not represented as a conventional food or the sole item of a meal, and it must be "labeled as a dietary supplement."

The definition also excludes articles approved as new drugs, or authorized for investigation as new drugs where substantial clinical investigations have been made public, unless the article was marketed as a supplement or food first. That drug-exclusion clause drives FDA's positions on CBD and several other ingredients. For an oral film, though, the clause that matters most is the one about ingestion.

Why sublingual and buccal absorption claims create drug-classification risk

An oral dissolving film dissolves in the mouth. Whether it is intended for ingestion or for absorption through the oral mucosa is a matter of labeling and marketing, and FDA has treated that distinction as decisive. In a February 5, 2019 warning letter on a sublingual melatonin product, FDA explained that dietary supplements must be intended for ingestion and that because the product was "intended to enter the body directly through the skin or mucosal tissues," it was not a dietary supplement and not a food. A May 18, 2021 warning letter on another sublingual product used the same reasoning: such products "are intended to enter the body directly through the skin or mucosal tissues" and fall outside the definition regardless of any other exclusion.

FDA's draft NDI guidance says the same thing from the other direction. It describes a dietary supplement as a product "which by definition is intended for ingestion," and lists a "different route of administration (e.g., an article that has a history of safe use in sublingual form and is now intended for ingestion as an NDI)" as a change that needs new safety support.

This is the single most important regulatory fact for an oral strip brand. A strip labeled as a dietary supplement that dissolves in the mouth and is swallowed sits on the supplement side. Copy that says the strip bypasses digestion, delivers the active to the bloodstream through the tissue under the tongue, or is for sublingual or buccal absorption describes a product not intended for ingestion, and FDA has treated such products as unapproved drugs.

StripWorks describes supplement strips as oral dissolving films taken by mouth for ingestion and avoids claims of bypassing digestion, sublingual absorption, or superior bioavailability unless a specific product has the evidence and classification to support them. Whether a particular label stays on the supplement side is a decision for the brand's regulatory counsel, made before the carton is printed.

21 CFR Part 111: cGMP for supplement manufacturers

Because FDA does not review supplements before sale, the burden sits with the firm. FDA states that "a firm is responsible for ensuring that the dietary supplements it manufactures or distributes are not adulterated, misbranded, or otherwise in violation of federal law" and must "follow current good manufacturing practices that help ensure the identity, purity, quality, strength, and composition" of the product. Those practices are 21 CFR Part 111, which applies to anyone who manufactures, packages, labels, or holds a dietary supplement.

Part 111's subparts read like a due-diligence checklist for an oral film manufacturer: personnel (B), physical plant (C), equipment (D), production and process control (E), quality control (F), components, packaging, and labels (G), the master manufacturing record (H), the batch production record (I), laboratory operations (J), manufacturing (K), packaging and labeling (L), holding and distributing (M), returned product (N), complaints (O), and records (P).

Four words matter in a quote: specification, master manufacturing record, batch record, release. The manufacturer must set specifications for components and finished product; verify them, including "at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient" (111.75(a)(1)) and finished-batch verification of "identity, purity, strength, composition" and contamination limits (111.75(c)); document every batch against the master record; and have quality control approve release. It must also hold reserve samples of each distributed lot, in the retail container-closure system, for one year past shelf life or two years from last distribution (111.83). Ask how each is done for your product and get the scope in writing. This guide describes the regulation and makes no claim about StripWorks' certifications or registrations, which are confirmed in project documents.

New dietary ingredients and the 75-day notification

A dietary ingredient not marketed in the United States before October 15, 1994 is a new dietary ingredient. Under 21 CFR 190.6, "at least 75 days before introducing or delivering for introduction into interstate commerce a dietary supplement that contains a new dietary ingredient" that has not been in the food supply in unaltered form, "the manufacturer or distributor of that supplement, or of the new dietary ingredient, shall submit" to FDA the basis for concluding the supplement "will reasonably be expected to be safe." FDA's consumer Q&A calls this the main exception to the rule that supplements can be marketed without notifying the agency.

A notification is not an approval. FDA reviews it, responds, and publishes the list of submissions, but a response that raises no objection is not a safety finding and does not transfer to another firm's ingredient or conditions of use.

For an oral film the NDI question arrives three ways. Trend-driven actives are often NDIs with no notification on file. Marketing that implies a different route brings the ingestion problem back. And the duty belongs to the manufacturer or distributor, so a brand cannot assume its contract manufacturer has handled it. Ask, in writing, whether each active's NDI status is resolved, and confirm with counsel.

Structure/function claims and the disclaimer

DSHEA lets a supplement label carry structure/function claims: statements that "describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function of the human body," such as calcium builds strong bones. FDA requires that "the manufacturer must have substantiation that the claim is truthful and not misleading and must submit a notification with the text of the claim to FDA no later than 30 days after marketing" the product. The claim may not state or imply that the product diagnoses, treats, cures, or prevents a disease; "only a drug can legally make such a claim."

The disclaimer is fixed text. Under 21 CFR 101.93(c) a label with one such statement must say: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." With more than one statement the plural form may be used. It sits adjacent to the claim or is linked to it with a symbol, and both the notification and the disclaimer apply to dietary supplements, not conventional foods.

For strips the claims that most often cross the line are delivery claims: faster absorption, higher bioavailability, bypasses the digestive system. They read as absorption-route claims (the ingestion problem again) and as comparative claims that need substantiation. The safer framing describes what the product is (a dissolving strip taken by mouth) and the ingredient's role in the diet, with the disclaimer, and leaves absorption physiology off the label.

Labeling basics under 21 CFR Part 101

FDA's Dietary Supplement Labeling Guide lists five statements every supplement label carries: a statement of identity naming the product as a dietary supplement, the net quantity of contents, nutrition labeling in Supplement Facts format, an ingredient list, and the name and place of business of the manufacturer, packer, or distributor. The statement of identity and net quantity go on the principal display panel; Supplement Facts, the ingredient list, and the name and place of business go on the information panel.

The Supplement Facts panel follows 21 CFR 101.36, which requires that "the label of a dietary supplement that is offered for sale shall bear nutrition labeling in accordance with this regulation" and specifies serving size, dietary ingredients and amounts per serving, percent Daily Value where one exists, and other ingredients. For a strip, serving size is in strips and net quantity is strips per package, which makes the 20-count versus 30-count decision a labeling decision as well as a commercial one.

Two things are specific to film. Sachets are labeling too; if a sachet leaves the carton, plan what the consumer sees across both. And the disclaimer, serving size, the adverse-event contact, and lot and expiration coding all have to fit on a small package, so layout starts before the dieline is final. Retail-channel and state-by-state requirements stay with the brand unless expressly included in the project.

Serious adverse event reporting

The Dietary Supplement and Nonprescription Drug Consumer Protection Act added a mandatory reporting duty. FDA's guidance: "The manufacturer, packer, or distributor whose name (pursuant to section 403(e)(1) of the FD&C Act) appears on the label of a dietary supplement marketed in the United States is required to submit to FDA all serious adverse event reports associated with use of the dietary supplement in the United States." Reports "must be submitted to FDA no later than 15 business days after the report is received by the responsible person," as must follow-up information received within one year, on MedWatch Form FDA 3500A or its electronic equivalent, and "the responsible person must maintain all records related to each report of a serious adverse event for a period of 6 years."

The responsible person is whoever's name is on the label. For a private-label strip that is the brand, not the contract manufacturer. Before launch, set up a monitored contact channel matching the label, a written procedure for deciding what counts as serious, and an agreement with the manufacturer on sharing complaints and adverse events, since Part 111 separately requires the manufacturer to handle complaints (Subpart O). The quality agreement should say who does what.

Child-resistant packaging and other packaging considerations

Child-resistant packaging for supplements is a Consumer Product Safety Commission rule under the Poison Prevention Packaging Act, and it is narrow. Under 16 CFR 1700.14(a)(13), dietary supplements containing the equivalent of 250 mg or more of elemental iron in a single package (above specified concentrations) must be child-resistant. Almost no oral strip formula carries iron at that level, so the federal rule usually does not apply.

That does not end the analysis. Strips are small, flavored, and packed in sachets that can look like candy to a child. Retailers, marketplaces, and destination markets set their own expectations above the federal floor. Whether to use a child-resistant carton or a tamper-evident sachet is a product decision made with counsel and the channel in mind; StripWorks offers child-resistant secondary packaging where law, channel, or customer specification calls for it.

Packaging is also part of the stability evidence under Part 111, since moisture is the main threat to an oral film. The sachet and carton belong in the specification, the stability plan, and the label review, not only the artwork brief.

Common questions

Primary sources

• FDA — Is It Really 'FDA Approved'?
• FDA — Questions and Answers on Dietary Supplements
• FDA — FDA 101: Dietary Supplements
• Public Law 103-417, Dietary Supplement Health and Education Act of 1994 (GovInfo, Statutes at Large)
• 21 U.S.C. 321 — definitions of 'drug' (g) and 'dietary supplement' (ff) (Office of the Law Revision Counsel)
• FDA — Over-the-Counter (OTC) Nonprescription Drugs
• FDA — Registration of Food Facilities and Other Submissions
• 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements (GovInfo, 2025 edition)
• 21 CFR Part 111 on eCFR (current text)
• FDA — New Dietary Ingredient (NDI) Notification Process
• 21 CFR 190.6 — Requirement for premarket notification (GovInfo)
• FDA — Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues (PDF)
• FDA Warning Letter — DK Vitamins (sublingual melatonin), February 5, 2019
• FDA Warning Letter — Umbrella (sublingual product), May 18, 2021
• FDA — Structure/Function Claims
• 21 CFR 101.93 — Certain types of statements for dietary supplements (GovInfo)
• FDA — Dietary Supplement Labeling Guide, Chapter I: General Dietary Supplement Labeling
• 21 CFR 101.36 — Nutrition labeling of dietary supplements (GovInfo)
• FDA — Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements
• 16 CFR 1700.14 — Substances requiring special (child-resistant) packaging (GovInfo)
• FDA — Premarket Tobacco Product Applications
• 21 CFR 111.75 — What must you do to determine whether specifications are met? (GovInfo)
• 21 CFR 111.83 — What are the requirements for reserve samples? (GovInfo)